Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2010 financial results after the Nasdaq market closes on Wednesday, July 28, 2010.  Neurocrine will then host a  live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, July 29, 2010 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

Participants can access the live conference call by dialing 1-800-894-5910, (US) or 785-424-1052 (International) using the conference ID: 7NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.  If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-753-5207 (US) or 402-220-2156 (International) using the conference ID: 7NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Global Rising Stars Outlook 2015" report ... treating diseases are being sought after with fresh vigor ... One field which is poised to bring a paradigm ... next decades is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... PARK, Calif. , March 5, 2015  Asterias ... in the emerging field of regenerative medicine, announced today ... of the nation,s top rehabilitation hospitals for spinal cord ... Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) ... cervical spinal cord injury (SCI). The ...
(Date:3/5/2015)... Mr Minoru Yoshizumi , President of ... , is pleased to announce the release of EggQus, ... the European Radiology Congress (ECR). Delegates will have the ... Medical Systems booth 323, Expo C.      ... (Photo: http://photos.prnewswire.com/prnh/20150305/732754-b ) , , ...
Breaking Medicine Technology:Global Pharma Rising Stars Outlook 2015 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 2Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 3
... CAMBRIDGE, Mass. , Feb. 1 Pervasis Therapeutics, Inc. ... Food and Drug Administration (FDA) on the design of a pivotal ... the prevention of hemodialysis access graft failure. The agreement was made ... initiate the study in 2010. , "We are pleased that ...
... Consumers Oppose Prescription Mandate; Prefer Alternative Method to Fighting Meth ... Mississippians are expressing outrage at lawmakers, rush to ... a prescription (Rx) drug. , "The Consumer Healthcare Products ... contact their legislators which within the first day fielded scores ...
Cached Medicine Technology:Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 2Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 4Mississippians React to Rushed Pseudoephedrine Debate Raging in the State Legislature 2Mississippians React to Rushed Pseudoephedrine Debate Raging in the State Legislature 3
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
(Date:3/5/2015)... 05, 2015 Wimbledon Health Partners ... vascular, echocardiogram and NCV testing, announced the ... Chief Medical Officer. Dr. Artel will be responsible for ... the WimbledonMED program and the continued growth and support ... working with Wimbledon Health Partners as a consulting physician ...
(Date:3/5/2015)... 05, 2015 Altec Products, Inc., a ... today their participation in the Houston, TX and Charlotte, ... Inspire Tour will unite Sage enterprise resource planning (ERP) ... workable solutions to real-world business challenges. , The ... Plaza Houston Galleria Area on March 10th. The Charlotte, ...
(Date:3/5/2015)... March 5, 2015 – As National Patient ... 8-14, 2015), children’s hospitals around the country are affirming ... stays as safe as possible for their children. , ... for Patient Safety (SPS) and the Children’s Hospital Association—are ... when visiting the hospital with their child. , ...
Breaking Medicine News(10 mins):Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 2Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4
... KING OF PRUSSIA, Pa., April 20 Universal Health Realty ... its Board of Trustees has appointed Randall C. Stein as ... Board of Trustees and the fifth independent Trustee. ... Realty, Inc. (since 1995), an integrated commercial real estate company ...
... Novartis) to the NCCN Guidelines for Kidney Cancer as ... whose disease has progressed after treatment with kinase inhibitors. ... 30, 2009 FDA approval of everolimus based upon results ... significantly extended progression-free survival in a specific group of ...
... Centers Improve Access; Deliver High-Quality Care with TechnologyTAMPA, ... a Health Resources and Services Administration (HRSA)-sponsored health ... of a successful collaboration among 54 community health ... Sage Intergy EHR for member community health centers ...
... screening rates but one that can be fixed, study ... doctor-patient communication and not having a regular primary-care doctor ... rates among black Americans, a new study suggests. , ... Baltimore, and found that those who,d been screened for ...
... Now Estimated to be at least $0.35 per Diluted ... Service Corporation (Nasdaq: PRSC ) today announced ... scheduled to present an overview of the Company,s operations ... April 21, 2009 at The Waldorf-Astoria Hotel in New ...
... Rita and Ike we saw a need to ... through chaos created by lack of access to ... critical care physician and CEO of PatientCentral Technologies. ... patients, their physicians, hospitals and other healthcare providers ...
Cached Medicine News:Health News:NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus 2Health News:NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus 3Health News:Health Choice Network Implements Sage Intergy CHC Community Health Management System and EHR Across Nation 2Health News:Health Choice Network Implements Sage Intergy CHC Community Health Management System and EHR Across Nation 3Health News:Doctor-Patient Talks Key to Blacks Getting Cancer Screens 2Health News:Providence Service Corporation to Present at the CIT 4th Annual Healthcare Conference on April 21 2Health News:Providence Service Corporation to Present at the CIT 4th Annual Healthcare Conference on April 21 3Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 3Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 4
... The Trinity Biotech Mumps IgM ... intended for the qualitative detection ... serum to Mumps for the ... performance characteristics of this kit ...
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
... The Xact stent is self-expanding and has ... yet highly flexible mesh intended to help restore ... a smooth inner vessel surface, and potentially reduce ... diseased vessel when it is treated, which can ...
Medicine Products: